

1 Systematic review of cardiac adverse effects in children and young people under 18
2 years of age after SARS-CoV-2 vaccination

3

4 Joana Cruz¹

5 Amedine Duret²

6 Rachel Harwood^{3 4}

7 Lorna K. Fraser⁵

8 Caroline B. Jones⁶

9 Joseph Ward¹

10 Elizabeth Whittaker^{2 7}

11 Simon E. Kenny^{2 7 8}

12 Russell M. Viner¹

13

14 ¹Population, Policy and Practice Department, UCL Great Ormond St. Institute of Child
15 Health, London, UK

16 ²Department of Paediatric Infectious Diseases, Imperial College Healthcare NHS Trust, Lon-
17 don, UK

18 ³Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool,
19 UK

20 ⁴Department of Paediatric Surgery, Alder Hey Children's Hospital, Liverpool, UK

21 ⁵Martin House Research Centre, University of York, York, UK

22 ⁶Alder Hey Children's Hospital, Liverpool, UK

23 ⁷Section of Paediatric Infectious Diseases, Faculty of Medicine, Imperial College London,
24 London, UK

25 ⁸NHS England and NHS Improvement, London, UK

26

27 Abstract

28 Background

29 Reports of myocarditis and pericarditis following vaccination with mRNA vaccines for SARS-
30 CoV-2 have occurred after countries began vaccinating adolescents. We undertook a sys-
31 tematic review of cardiac adverse effects associated with SARS-CoV-2 vaccine in children
32 and young people (CYP) < 18 years.

33 Methods

34 Systematic review with protocol prospectively registered with PROSPERO
35 (CRD42021275380).

36 Six electronic databases were searched from 1 December 2019 to 14 September 2021. Eligi-
37 ble studies were those reporting on CYP with reported or proven myocarditis, pericarditis
38 and/or myopericarditis associated with vaccination against SARS-CoV-2. We summarized
39 findings across all clinical cases reported in case report / case series studies. As a number of
40 studies reported data from two publicly available vaccine surveillance systems, we updated
41 estimates of reporting rates for cardiac adverse events up to 31 October for the US Vaccine
42 Adverse Event Reporting System (VAERS) and 13 November for EudraVigilance covering Eu-
43 ropean Union and European Economic Area (EUEA) countries.

44 Results

45 Twenty-one studies were included from 338 identified records. Seventeen were case re-
46 ports/series describing a total of 127 CYP. Three studies described reporting rates from pas-
47 sive surveillance databases (VAERS, EudraVigilance, and the WHO VigiBase) and one de-
48 scribed 22 cases from the US Vaccine Safety Datalink (VSD).

49 Clinical series reported that 99.2% presented with chest pain, 100% had raised troponin and
50 73.8% had an abnormal ECG. Cardiovascular magnetic resonance (CMR) in 91 cases identi-
51 fied myocardial injury in 61.5%, with 90.1% showing late gadolinium enhancement. NSAIDs
52 were the most common treatment (76.0%).

53 One US dataset (VSD) estimated a significant excess of 29.6 events per million vaccine doses
54 across both sexes and doses. There were 1129 reports of myocarditis and 358 reports of
55 pericarditis from across the USA and EU/EEA. The VAERS reporting rate per million for myo-
56 carditis was 12.4 for boys and 1.4 for girls after the first dose, and 49.6 for boys and 6.1 for
57 girls after the second dose. There was a marked trend for VAERS reporting to be highest
58 soon after initiation of the vaccine schedule, suggesting reporting bias.

59 Conclusions

60 Cardiac adverse effects are very rare after mRNA vaccination for COVID-19 in CYP <18 years.
61 The great majority of cases are mild and self-limiting without significant treatment. No data
62 are yet available on children under 12 years. Larger detailed longitudinal studies are ur-
63 gently needed from active surveillance sources.

64

65 Introduction

66 The introduction of vaccines to protect against serious illness in SARS-Cov-2 has been highly
67 effective ¹. However, there have been a number of case reports describing cardiac adverse
68 effects, namely myocarditis, pericarditis and myopericarditis after SARS-CoV-2 vaccination ²
69 ³. From May 2021 onward, several countries extended vaccination to include children and
70 young people (CYP) aged 12-15 years old ^{4,5}. Soon after this, reports were published of cases
71 of myocarditis in CYP after SARS-CoV-2 vaccination, especially in males ⁶. Myocarditis and
72 associated conditions have also been reported after SARS-CoV-2 infection, both with COVID-
73 19 disease ⁷⁻⁹ and with the post-infectious paediatric multisystem inflammatory syndrome
74 (PIMS) ¹⁰, also known as multisystem inflammatory syndrome in children (MIS-C).

75 By October 2021, several reports had been published with wide variation in reported fre-
76 quency of myocarditis after vaccination ^{9,11,12}. The frequency of myocarditis in these studies
77 varied according to gender, age group and whether first or second dose administered ^{13,14}.

78 Estimates across broader age-groups using high-quality data sources suggest the risk of my-
79 ocarditis was highest amongst young men, with estimated incidence after the first dose of
80 106.9 per million amongst males 16-29 years,¹¹ and 13.4 and 150.7 per million after first and
81 second doses respectively.¹² Males aged 12-15 years old appeared most affected, particu-
82 larly after the second dose.^{13,14}

83 As of early November 2021, over 50 million doses of mRNA vaccines have been given to 12-
84 17 year olds across the USA¹⁵ and European Union and European Economic Area¹⁶ countries,
85 with an additional 2.8 million doses given in the UK¹⁷ and 3.1 million in Australia.¹⁸

86 Establishing the nature and frequency of vaccination adverse events such as myocarditis is
87 essential to inform both national vaccination strategies and clinical decision-making for indi-
88 viduals, particularly as nations expand adolescent vaccination and consider vaccinating
89 younger children. We therefore undertook a systematic review of cardiac adverse effects
90 associated with SARS-CoV-2 vaccine in those under 18 years.

91

92 Methods

93 We followed a standardised methodology and reported results according to Preferred Re-
94 porting Items for Systematic Reviews and Meta-Analyses (PRISMA) ¹⁹ recommendations.
95 The protocol was prospectively registered with PROSPERO (CRD42021275380).

96 Review question

97 What are the characteristics, frequency and natural history of cardiac adverse effects in chil-
98 dren and young people (CYP) (<18 years old) after SARS-CoV-2 immunisation?

99 Search strategy

100 We systematically searched PubMed, MedRxiv, Europe PMC, World Health Organisation's
101 COVID-19 Global Literature on Coronavirus Disease, Research Square and Google Scholar

102 from 1 December 2019 to 14 September 2021 for peer-reviewed papers and reports on car-
103 diac adverse events caused by SARS-CoV-2 immunisation in CYP. The search strategy used
104 the keywords “myocarditis” OR “pericarditis” OR “adverse effects” AND “covid-19” AND
105 “vaccin*” AND “children” OR “adolescent” OR “paediatric” in title or abstract of the refer-
106 ence. The complete list of key word strings for each database can be found in supplemen-
107 tary appendix (Table S1). The first 40 results from Google Scholar were also analysed, along
108 with the databases of the US Vaccine Adverse Event Reporting System (VAERS)²⁰ and Eudra-
109 Vigilance—the European database of suspected adverse drug reaction reports²¹ for cases of
110 myocarditis, pericarditis or myopericarditis related with SARS-CoV-2 vaccine in CYP aged be-
111 tween 12-17 years old. We included adverse effects from mRNA-1273 (Moderna) and BNT
112 162b2 (Pfizer) vaccines since they were the only vaccines approved for the age group <18
113 years old at the time of writing of this paper.

114 Eligibility

115 We included papers that reported myocarditis, pericarditis and/or myopericarditis associ-
116 ated with vaccination against SARS-CoV-2 in CYP, aged <18 years old. Studies that also in-
117 cluded individuals older than 18 years old were included if they allowed extraction of data
118 on eligible individuals and/or age groups separately. We excluded studies on CYP SARS-CoV-
119 2 vaccination trials (being underpowered), systematic reviews that mentioned cardiovascu-
120 lar involvement but did not specify the above conditions, studies that included patients with
121 cardiovascular conditions diagnosed prior to SARS-CoV-2 vaccination or that used non-hu-
122 man models. Where multiple studies reported data from vaccine surveillance databases, we
123 included only the most recent studies to avoid duplication.

124 Study selection

125 The PRISMA flowchart is shown in figure 1. Our search identified 330 articles to which we
126 added eight articles identified through the snowball technique. Titles and abstracts of po-
127 tentially eligible articles and full-text review were scrutinised by one investigator (JC). Of
128 those, 271 were ineligible based on criteria and 46 articles were excluded as duplicates, with
129 21 articles included in this review.

130 Data extraction

131 The following information was extracted from included studies: author and year of publica-
132 tion, type of study (cohort, case report or case series), number of cases, case source, pa-
133 tients’ sex, median age and range, vaccine type, percentage of patients presenting symp-
134 toms after second vaccination, percentage of patients with symptoms resolved, median and
135 range hospitalisation days and diagnoses of cardiac adverse effects. For the diagnostic crite-
136 ria and treatment, we extracted the patients’ symptoms, troponin and c-reactive protein
137 blood serum concentration, and observations from electrocardiogram, echocardiogram and
138 cardiovascular magnetic resonance, as well as treatment provided. These data were ex-
139 tracted to a spreadsheet by one reviewer (JC) and checked by two reviewers (JW, AD). They
140 reached agreement regarding any conflicting results.

141 Quality evaluation

142 Quality evaluation of case reports/case series was assessed using the case-report (CARE) 13-
143 item guideline²². This guideline comprises 30 sub-items. Each item ratings are 'yes' or 'no',
144 and the final quality evaluation score was the sum of sub-items. The quality evaluation was
145 performed independently by two reviewers (JC and AD) and in case of disagreement, a third
146 reviewer (LF) made the final decision. Quality evaluation for each case report/case series are
147 available in supplementary material (Table S2).

148 Data synthesis

149 We considered data from case reports/case series separately from the data extracted from
150 databases reporting adverse effects of vaccination against SARS-CoV-2. Data from three pas-
151 sive surveillance databases were used in included studies; the European Medicines Agency's
152 European database of suspected adverse drug reaction reports (EudraVigilance, covering Eu-
153 ropean Union and European Economic Area countries)²¹, the Centers for Disease Control
154 (CDC) Vaccine Adverse Event Reporting System (VAERS, covering the USA),²⁰ and the World
155 Health Organisation's global Individual Case Safety Report Database, VigiBase²³. More than
156 130 countries contribute to VigiBase although more than 85% of adverse effects caused by
157 BNT162b2 (Pfizer) vaccine were reported from countries in Europe and America²⁴. As
158 above, we only included the most recent studies from these databases. Data were available
159 from one active surveillance system, the CDC's Vaccine Safety Datalink (VSD)²⁵ which is a
160 collaboration between the CDC and eight managed care organisations covering 3.6% of the
161 US population. Participating VSD sites file weekly reports of medically-attended (clinic,
162 emergency department or hospital) adverse events of COVID-19 vaccination for total 10.2
163 million participants aged ≥ 12 years.

164 *Additional data*

165 We additionally updated estimates from EudraVigilance²¹ and VAERS²⁰. We calculated
166 crude reporting rates for cardiac adverse events per million doses administered used the
167 denominator being the sum of first dose and all fully vaccinated CYP as of 6 November 2021
168 for European Union and European Economic Area countries¹⁶ and 31 October 2021 for the
169 USA.¹⁵ For the USA, but not EU countries, we were also able to stratify adverse effects and
170 calculate crude rates by sex and by dose, using data on proportional US adolescent vaccine
171 uptake by sex following previous reports.²⁶ For EU/EEA countries, we considered a time lag
172 of 7-days to consider both reporting lag and a pre-defined 7-day risk window, following previ-
173 ous reports¹⁴; for USA VAERS, we used the vaccination month reported. For this dataset, we
174 were able to repeat these analyses by month of vaccination from December 2020 to October
175 2021.

176 Results

177 Our review included 21 articles^{14 23 27-44} together with updated data from EudraVigilance²¹
178 and VAERS²⁰.

179 *Case series/case reports*

180 Seventeen articles were case reports or series that described between one^{31 34 35 40} and 31³²
181 patients aged <18 years, with a total sample of 127 (see Table 1). Most were from the USA
182 (82%)^{28-30 32-38 40-43}, with 2 from Israel^{27 39} and 1 from Germany³¹. 92.1% of cases were male
183 and the median age ranged between 15 and 17 years. Sixteen described occurrence of car-
184 diac adverse events after vaccination with BNT162b2 (Pfizer) vaccine and one study included
185 cases after Pfizer or Moderna (mRNA-1273) vaccines³². Events were observed after admin-
186 istration of second dose (92.1%) with onset symptoms within 2^{27 28 32 33 39 41-43} and 4.5³⁰
187 days (median).

188 Sixty-four patients had myocarditis^{27 29 31-33 35 36 38 40 42 43} and 56 myopericarditis.^{28 30 34 37 39 41}
189 A further 14 patients aged 12-20 years in one study³² were considered to have clinically sus-
190 pected myocarditis although the number 12-17 years was not specified. No patients 0-17
191 years died of cardiac adverse effects after vaccination in any study. Where reported, the
192 median hospitalisation days ranged between 2^{29 37 41} and 7³¹ days, and all made full clinical
193 recovery^{28 30-37 39 42 43} except 14 patients^{29 33 42}. In the latter cases, at the time of discharge,
194 three patients had mildly elevated troponin levels, one had persistent borderline low left
195 ventricular systolic function on echocardiogram (EF 54%) and another had non-sustained
196 ventricular tachycardia.²⁹ Three patients had abnormal cardiovascular magnetic resonance
197 (CMR) results with late gadolinium enhancement (LGE).²⁹ Six patients' ECGs, at follow-up,
198 revealed persistent changes, either nonspecific T-wave changes^{33 29}, T-wave inversion²⁹ or
199 a repolarisation abnormality.⁴² Clinical and laboratory findings and treatment given are
200 summarized across the 17 case studies/series in Table 2. Presentation was most commonly
201 with acute chest pain followed by fever and shortness of breath (Table 2). All patients had
202 an elevated troponin (more significant in those with myocarditis) and most a raised CRP.
203 73.8% of patients had an abnormal ECG at presentation, typically with ST elevation or dif-
204 fuse ST changes in addition to T wave inversion. Echocardiographic assessment showed nor-
205 mal left ventricular wall geometry and preserved systolic function in the majority. CMR im-
206 aging was undertaken in 91 cases with findings suggesting myocardial injury including 56
207 (61.5%) with myocardial oedema and 82 (90.1%) with LGE. Systolic or diastolic dysfunction
208 was only evident in 5.6% and 7.7%, by echo or CMR assessment, respectively, and 11.3%
209 and 20.9% of patients were noted to have pericardial effusion also by echo or CMR assess-
210 ment.

211 Treatment most commonly used nonsteroidal anti-inflammatory agents (NSAIDs; 76.0%).
212 Small numbers (14.9%) were treated with corticosteroids. Immunomodulatory therapy in
213 the form of IVIG was used in 19.8% as treatment for myocarditis. Small numbers received
214 diuretics or angiotensin-converting enzyme (ACE) inhibitors (Enalapril; 1.7%) to treat left
215 ventricular systolic dysfunction, or colchicine (2.5%) to prevent recurrent pericarditis. No pa-
216 tients required inotropic or mechanical support. Two (1.7%) patients required no treatment.

217 *SARS-CoV-2 vaccination adverse effects reported from databases – systematic review*

218 Three included studies used data extracted from passive vaccine surveillance systems, the
219 EudraVigilance⁴⁴, VAERS^{20 44} and VigiBase²³ databases with most recent data being from 30
220 June 2021 (VigiBase²³), 6 August 2021 (EudraVigilance⁴⁴) and 18 August 2021 (VAERS²⁰).

221 We included also a study using Vaccine Safety Database (VSD) data, which included three
222 reports.⁴⁵⁻⁴⁷

223 VAERS data on reported cases of myocarditis per million amongst US 12-15 year old boys
224 were 4.8 and 42.6 for first and second dose of the Pfizer vaccine¹⁴. For girls of the same age
225 group, the cases of myocarditis were 0.5 and 4.3 per million of per million of first and sec-
226 ond dose of Pfizer vaccine, respectively¹⁴. For age group 16-17, the number of cases in-
227 creased. After the first dose, there were 5.2 and 0.0 cases of myocarditis per million of Pfizer
228 vaccine administrated, in boys and girls respectively¹⁴. After the second dose, the numbers
229 increased to 71.5 and 8.1 cases per million of Pfizer vaccine administrated, respectively¹⁴.
230 Cases of myocarditis after administration of Moderna vaccine were only reported in boys
231 aged 16-17; after the second dose, 31.2 cases per million of Moderna vaccine adminis-
232 trated.¹⁴

233 Only one study published data extracted from EudraVigilance, reporting 61 cases of myocar-
234 ditis and 14 of pericarditis, in CYP aged 12-17 years, after at least one dose of Pfizer or
235 Moderna vaccines, by 6 August 2021⁴⁴. These adverse cardiac effects affected mostly boys
236 (myocarditis: 87%; pericarditis: 64.3%) and were predominantly after Pfizer vaccine (myo-
237 carditis: 98.3%; pericarditis: 100%) rather than Moderna vaccines⁴⁴. Relationship to dose-
238 number and frequency of events per million doses were not available for 12-17 year olds.
239 Whilst some deaths were reported post-vaccine across all ages, data were not available to
240 identify whether within the CYP age-range.

241 The study from VigiBase reported 291 events after the Pfizer vaccine and 3 after the
242 Moderna vaccine; 249 events were myocarditis and 45 were pericarditis, with no deaths
243 amongst the 12-17 year age-group²³. Compared with females, the odds of myocarditis was
244 12.0 (95% CI: 7.9-18.3) for males 12-17 years, with odds for pericarditis amongst boys com-
245 pared with girls being 12.7 (95% CI: 4.5-35.5)²³.

246 The study using VSD data (3 reports)⁴⁵⁻⁴⁷ identified 22 events in the 21 days after SARS-CoV-
247 2 vaccination amongst US 12-17 year olds in data from December 2020 to 21 August 2021.
248 These were a subgroup of a larger sample of 100 cases amongst 12-39 year olds of which 78
249 (78%) were considered to be true cases of myo- or pericarditis after expert review. Amongst
250 the 22 proven cases in 12-17 year olds, 50% (n=11) had acute myocarditis, 45% (10) myoper-
251 icarditis and 5% (1) had acute pericarditis. All (22) presented with chest pain and 64% (14)
252 had shortness of breath. 95% (21) had elevated troponin, 73% (16) had an abnormal ECG
253 and 43% (9/21) had an abnormal echocardiogram. 82% (18) were male with a median onset
254 of symptoms of 2 days. 86% (19) were hospitalised (32% (7) to intensive care) and all were
255 discharged home, with 59% discharged within 2 days.⁴⁵ Using additional data to 10 Septem-
256 ber 2021⁴⁶ on 12-17 year olds, they estimated that for the Pfizer vaccine only (30 confirmed
257 events), there was a significant excess of 29.6 events per million vaccine doses across both
258 sexes and doses, when compared with vaccinated adolescents 22-42 days after each dose,
259 adjusted for site, sex, ethnicity and date. Estimates were 3.8 per million for first doses (not
260 significantly different to zero) and 56.7 per million (significantly different to zero, confidence
261 intervals not reported) for second doses. Three-month follow-up data were available on 16

262 of the cohort after Pfizer-BioNTech vaccination, of whom 4 (25%) were still symptomatic
263 and 2 (13%) remained on medication, although no data were available on a control group.

264 *Updated data on SARS-CoV-2 vaccination adverse effects from VAERS and EudraVigilance*
265 We updated the data on cardiac events post vaccination amongst 0-17 year olds in VAERS
266 and EudraVigilance to the latest available data at the time of writing (17 November 2021)
267 (Table 3; Figure 2).

268 In the USA, 406 cases of myocarditis and 120 of pericarditis were reported to VAERS²⁰ by 31
269 October 2021. In the EU/EEA, 723 cases of myocarditis and 238 of pericarditis were reported
270 by 13 November 2021 (Table 3). Total number of cardiac events were not calculated due to
271 potential duplicate reporting across these categories.

272 Two reports recorded death after Pfizer vaccination. One from VAERS was a 15 year old
273 male who died of drowning five days after his second vaccine dose. Autopsy identified in-
274 creased left ventricular wall thickness and a small focus of myocardial inflammation but a
275 normal pericardium. Genetic analysis of 92 genes associated with inherited cardiomyopa-
276 thies and arrhythmias identified two variants of unknown significance. The second, from Eu-
277 draVigilance, was a health professional report of the death of a 12-17 year old male after his
278 second vaccine dose, with no further data beyond myocarditis, headache and fever.

279 Figure 2 shows the reporting rate of myocarditis and pericarditis in these two datasets. The
280 rate in the reporting EU/EEA countries was 27.9 and 9.2 cases respectively of myocarditis
281 and pericarditis per million vaccines administered.²¹ For the USA, the reporting rate was
282 16.2 and 4.8 cases per million of SARS-CoV-2 respectively.¹⁵ A higher percentage of male ad-
283 olescents than females reported cardiac adverse effects for both conditions studied (myo-
284 carditis: 86.6% (EU/EEA)²¹ and 88.7% (USA)²⁰; pericarditis: 72.3% (EU/EEA)²¹ and 85.8%
285 (USA)²⁰) (Table 3).

286 Only the USA VAERS provided data on the relationship of adverse events to vaccine dose;
287 the rate of myocarditis per million after first dose was 12.4 for boys and 1.4 for girls, and
288 49.6 for boys and 6.1 for girls after the second dose. The reporting rate of pericarditis fol-
289 lowed a similar trend. Across both sexes, the majority of cardiac events were reported after
290 the second dose (myocarditis: 77.1%; pericarditis: 75.0%).

291 Again, only VAERS provided data on time to onset of symptoms and duration of hospitalisa-
292 tion. Median onset of symptoms was two days (range: 0 to > 120 days) after immunisation
293²⁰. The median days that CYP were hospitalised was two (ranging from no need of hospitali-
294 sation to two months)²⁰.

295 VAERS data for myocarditis and pericarditis events by month of vaccination are shown in
296 Figure 3. For myocarditis, these show a trend for events after first and second doses to be
297 higher soon after initiation of that element of the vaccine schedule (February 2021 for first
298 dose, April 2021 for second doses). Incidence of events after second dose fell each month
299 from July onwards, a pattern also seen in females. In the most recent months (September-
300 October 2021), incidence of myocarditis after first doses was 7.6-12.3 in males and 0 in fe-
301 males, and after second dose 13.1-31.1 for males and 1.3-2.5 per million for females.

302 Incidence of pericarditis after the second dose in males appeared to follow a similar trend,
303 being highest in February and April 2021 and falling thereafter. Incidence in the most recent
304 two months was 2.6-4.1 per million for males and 0-1.3 for females.

305 Discussion

306 Our systematic review provides a comprehensive and up-to-date (November 2021) synthe-
307 sis of reported data on cardiac adverse effects in CYP < 18 years after SARS-CoV-2 immunisa-
308 tion. Detailed clinical data were available on 127 cases across 17 studies, active surveillance
309 data on 30 confirmed cases, and passive surveillance data on 1129 reports of myocarditis
310 and 358 reports of pericarditis from across the USA and EU/EEA. It is highly likely that some
311 or all of the clinical cases and active surveillance cases were contained within the passive
312 surveillance reports. Events were also reported through the WHO VigiBase database, alt-
313 hough the degree to which these events overlapped with the US and EU/EEA reports is un-
314 clear as these countries make up around 70% of VigiBase reports.

315 Clinical data were highly consistent across the three sources of data. The majority of cases
316 occurred in males aged 15-17 years old who presented with chest pain, elevated serum tro-
317 ponin and C-reactive protein and an abnormal ECG with ST elevation. Fewer presented un-
318 der age 15 years. We identified no cases under 12 years of age although very few doses
319 have been given in this age group. Most presented with chest pain around 2 days after vac-
320 cination, predominantly their second dose. Almost all had high troponin levels, 73.8% had
321 an abnormal ECG with variable echocardiography findings. Approximately 85% were hospi-
322 talised for short periods, with the great majority discharged within 2-7 days without treat-
323 ment other than non-steroidal anti-inflammatory drugs. While longer-term data were only
324 available on 16 young people from the VSD study, few remained on medication at 3 months.
325 The clinical picture of myocarditis post-COVID-19 vaccination amongst 12-17 year olds was
326 broadly similar to that previously reported across all ages.^{11 12}

327 There were no deaths in the clinical series nor in the active surveillance series, and none in
328 the clinical series required significant cardiovascular or respiratory support. There were two
329 male deaths reported in the passive surveillance data, although a causal link cannot be at-
330 tributed to vaccination, given that all deaths within a 21 day period after vaccination maybe
331 reported regardless of causation. It is important to note that in 2019 in the USA there were
332 approximately 12 deaths males aged 12-17 years each day, with approximately 250 occur-
333 ring in the average 21 day period, from a range of traumatic and medical causes.⁴⁸ Given
334 that over 40% of 12-17 year olds in the USA have had at least one dose,²⁶ this suggests that
335 there are likely to be a considerable number of deaths of adolescent boys soon after vac-
336 cination for reasons entirely unconnected with vaccination. Broader analysis of VAERS re-
337 ports of deaths from myocarditis associated with COVID-19 vaccination across a broader
338 age-group is reassuring that almost all reported cases are not vaccination-related. As of
339 early November, 8 deaths were identified in those aged <30 years with possible concern for
340 myocarditis after approximately 86 million vaccine doses; 3 were assessed as not being my-
341 ocarditis, 3 as due to infectious (i.e. non-vaccine) myocarditis whilst evaluation was ongoing
342 in 2 cases.⁴⁷

343 Data from active surveillance suggest a significant excess of confirmed myo- or pericarditis
344 events in the 21 days post-vaccination compared with matched adolescents 22-42 days after
345 vaccination, supporting a causal link for myocarditis with the Pfizer-BioNTech vaccine alt-
346 hough numbers of events were low in this age-group. Passive surveillance data from VAERS
347 and EudraVigilance provide an estimate of the reporting rate for unconfirmed events and
348 cannot infer causality. These differences in data quality and estimation methods means that
349 estimates are not directly comparable across the datasets, although estimates were broadly
350 similar. Overall estimates across both sexes and both doses across the period were approxi-
351 mately 30 per million for myo-pericarditis for VSD and 17 and 28 per million for myocarditis
352 in VAERS and EudraVigilance respectively. Estimates for events post first dose were approxi-
353 mately 4 per million from VSD and 1.4 and 12.4 for females and males respectively in VAERS.

354 However the time trends we identified in VAERS data for males suggest that the summary
355 estimates across the study period are highly likely to be biased upwards. Estimates were
356 higher amongst males after the second dose across the study period, however the monthly
357 crude estimate decreased notably in the most recent 3 months. Whilst the most recent
358 month may be lower due to incomplete reporting, previous studies showing higher levels of
359 reporting in VAERS following publicity relating to claimed adverse events,⁴⁹ suggest that
360 lower estimates from August and September 2021 (31.1-39.7 per million second doses) may
361 be less biased, although trends may be continuing. It is unclear whether similar trends have
362 occurred in notifications to EudraVigilance as trend data are not publicly available. Whilst
363 there was no similar trend for events post first dose, it is notable that passive surveillance
364 reports from the UK, which began vaccinating healthy adolescents from September 2021,
365 more recently than the USA or many EU countries, identified a reporting rate of 0.8 events
366 per million amongst 0-17 year olds after approximately 2.8 million doses of the Pfizer-BioN-
367 Tech vaccine, the great majority being first doses.⁵⁰

368 Post-vaccination myocarditis must be seen in the context of myocarditis related to SARS-
369 CoV-2 infection, post-COVID syndromes and other causes of myocarditis. A large Israeli
370 study found the risk of vaccine-related myocarditis was found to be approximately 4-fold
371 less than the risk of myocarditis due to SARS-CoV-2 infection across age-groups,⁹ although
372 similar data are not available for the adolescent age-range. The post-COVID-19 Paediatric
373 Inflammatory Multisystem Syndrome (PIMS) has well described cardiovascular involvement.
374 Paediatric patients may present with cardiogenic shock, ECG abnormalities, myocardial dys-
375 function and coronary artery dilation ¹⁰, with 71-75% patients being admitted to Paediatric
376 Intensive Care Unit (PICU) ^{51 52} although the risk of death is very low.⁵³ Further, the clinical
377 picture and outcomes of myocarditis post-COVID-19 vaccination appear quite different to
378 established causes of acute myocarditis in CYP, which occurs in around 8 per million CYP⁵⁴
379 and has a higher incidence of left ventricular dysfunction and arrhythmia, median length of
380 stay 6-7 days,^{54 55} and mortality of up to 3-8%.^{54 56 57}

381 Other vaccines have rarely been linked with cardiac adverse effects.^{58 59 60} A reviewed of
382 VAERS reports of myopericarditis after vaccination between 1990 and 2018 found 99 re-
383 ports of myopericarditis in CYP, with most cases reported after *Haemophilus influenza* type
384 b (22, 22%) and hepatitis B (18, 18%) vaccination ⁶⁰. Most cases reported were in males (55,

385 56%), of high severity (40, 40%), and resulted in death in 55% of cases,⁶⁰ although this may
386 reflect biased reporting only of severe cases.

387 *Limitations*

388 Our findings are subject to a number of limitations inherent in systematic reviews and in the
389 data sources used. Publication bias towards greater severity is likely amongst the cases re-
390 ported in the 17 case study/series studies, which may not be representative of the less se-
391 vere cases.

392 Estimates from vaccine passive surveillance systems such as VAERS and EudraVigilance pro-
393 vide a reporting rate rather than an estimate of excess events, and are crude indicators of
394 risks related to vaccines.⁶¹ They cannot attribute causality between vaccine and reported
395 event, lack a comparison group, data quality is highly variable and they are open to a series
396 of biases from over- and -under-reporting.⁶² VAERS in particular has been criticised as open
397 to over-reporting by those opposed to COVID-19 vaccination.^{63 64} However all reports are
398 regularly scrutinized to remove duplicate and reports identified as fraudulent,⁶² although
399 the extent and timeliness of this is unclear. Passive surveillance systems are most useful for
400 identifying potential safety signals that require further investigation⁶² through more de-
401 tailed smaller studies using active systems such as the Vaccine Safety Datalink (VSD). The
402 VSD data included here provide an estimate of excess events, but the VSD can lack power to
403 examine small risks in specific populations²⁵ such as the CYP studied here.

404 Our data focus on 12-17 year olds and should not be regarded as informative for younger
405 children, as very few received COVID-19 vaccination during the period of study here. We
406 were unable to include data from some large all-age studies¹² as these did not provide data
407 specifically for those <18y. We were unable to further breakdown VAERS data by age within
408 the adolescent range; a CDC report from October 2021 reported that pooled risk for 16-17
409 year olds was higher after the second dose (69.1 per million) than amongst 12-15 year olds
410 (39.9 per million).⁴⁷ We estimated sex-specific reporting rates from VAERS data using pro-
411 portional differences in vaccine uptake in US adolescents. We were unable to compare risk
412 of cardiac events after the Pfizer-BioNTech and Moderna vaccines in this age group due to
413 lack of data. We were further unable to comment on risk of myocarditis after third doses
414 due to lack of data as no country has introduced booster doses for this age-group.

415 *Conclusions*

416 Cardiac adverse effects are very rare after use of mRNA vaccination for COVID-19 in CYP <18
417 years. The great majority of cases are mild and self-limiting without significant treatment, in
418 contrast to viral myocarditis. No data are yet available on children under 12 years and these
419 are awaited as vaccination of 5 to 11 year olds is rolled-out in some countries. Larger de-
420 tailed prospective longitudinal studies from active surveillance sources on both children and
421 adolescents are urgently needed to better understand the frequency and natural history of
422 the condition.

423

424

425 Funding

426 JC, SEK and RMV are in receipt of a grant from the National Institute of Health Research to
427 support this work (grant number NIHR202322). LKF is funded by a National Institute for
428 Health Research (NIHR) Career Development Fellowship (award CDF-2018-11-ST2-002).

429 Funders had no role in the design, data collection, analysis, decision to publish, or prepara-
430 tion of the manuscript.

431

432 References

- 433 1. Evans SJW, Jewell NP. Vaccine Effectiveness Studies in the Field. *N Engl J Med*
434 2021;385(7):650-51. doi: 10.1056/NEJMe2110605 [published Online First:
435 2021/07/22]
- 436 2. Diaz GA, Parsons GT, Gering SK, et al. Myocarditis and Pericarditis After Vaccination for
437 COVID-19. *JAMA* 2021;326(12):1210-12. doi: 10.1001/jama.2021.13443 [published
438 Online First: 2021/08/05]
- 439 3. Simone A, Herald J, Chen A, et al. Acute Myocarditis Following COVID-19 mRNA
440 Vaccination in Adults Aged 18 Years or Older. *JAMA Intern Med* 2021 doi:
441 10.1001/jamainternmed.2021.5511 [published Online First: 2021/10/05]
- 442 4. European Medicines Agency (EMA). COVID-19 vaccine Spikevax approved for children
443 aged 12 to 17 in EU European Medicines Agency (EMA)2021 [Available from:
444 [https://www.ema.europa.eu/en/news/covid-19-vaccine-spikevax-approved-](https://www.ema.europa.eu/en/news/covid-19-vaccine-spikevax-approved-children-aged-12-17-eu)
445 [children-aged-12-17-eu](https://www.ema.europa.eu/en/news/covid-19-vaccine-spikevax-approved-children-aged-12-17-eu) accessed 05/10/2021 2021.
- 446 5. US Food & Drug Administration. Comirnaty and Pfizer-BioNTech COVID-19 Vaccine: US
447 FDA; 2021 [Available from: [https://www.fda.gov/emergency-preparedness-and-](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine)
448 [response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine)
449 [19-vaccine](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine) accessed 05/10/2021 2021.
- 450 6. Vogel G, Couzin-Frankel J. Israel reports link between rare cases of heart inflammation
451 and COVID-19 vaccination in young men. *Science* 2021;10
- 452 7. Ojha V, Verma M, Pandey NN, et al. Cardiac Magnetic Resonance Imaging in Coronavirus
453 Disease 2019 (COVID-19): A Systematic Review of Cardiac Magnetic Resonance
454 Imaging Findings in 199 Patients. *J Thorac Imaging* 2021;36(2):73-83. doi:
455 10.1097/rti.0000000000000574 [published Online First: 2020/12/12]
- 456 8. Boehmer TK, Kompaniyets L, Lavery AM, et al. Association Between COVID-19 and
457 Myocarditis Using Hospital-Based Administrative Data - United States, March 2020-
458 January 2021. *MMWR Morb Mortal Wkly Rep* 2021;70(35):1228-32. doi:
459 10.15585/mmwr.mm7035e5 [published Online First: 2021/09/03]
- 460 9. Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19 Vaccine in
461 a Nationwide Setting. *N Engl J Med* 2021;385(12):1078-90. doi:
462 10.1056/NEJMoa2110475 [published Online First: 2021/08/26]
- 463 10. Alsaied T, Tremoulet AH, Burns JC, et al. Review of Cardiac Involvement in Multisystem
464 Inflammatory Syndrome in Children. *Circulation* 2021;143(1):78-88. doi:
465 10.1161/circulationaha.120.049836 [published Online First: 2020/11/10]
- 466 11. Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 Vaccination in a Large
467 Health Care Organization. *N Engl J Med* 2021 doi: 10.1056/NEJMoa2110737
468 [published Online First: 2021/10/07]
- 469 12. Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 mRNA Vaccine against
470 Covid-19 in Israel. *N Engl J Med* 2021 doi: 10.1056/NEJMoa2109730 [published
471 Online First: 2021/10/07]
- 472 13. Gargano JW, Wallace M, Hadler SC, et al. Use of mRNA COVID-19 Vaccine After Reports
473 of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on
474 Immunization Practices - United States, June 2021. *Mmwr-Morbidity and Mortality*
475 *Weekly Report* 2021;70(27):977-82.
- 476 14. Su JR. Myopericarditis following COVID-19 vaccination: Updates from the Vaccine
477 Adverse Event Reporting System (VAERS) CDC COVID-19 Vaccine Task Force, 2021.


- 478 15. Centers for Disease Control and Prevention. COVID-19 Vaccination Demographics in the
479 United States, National 15/09/2021 ed. CDC, 2021.
- 480 16. European Centre for Disease Prevention and Control (ECDC). COVID-19 Vaccine Tracker.
481 Stockholm: ECDC, 2021.
- 482 17. Coronavirus vaccine - weekly summary of Yellow Card reporting: updated 19 November
483 2021: Medicines and Healthcare products Regulatory Agency (MHRA), 2021.
- 484 18. COVID-19 vaccination – vaccination data – 1 November 2021: Australian Government -
485 Department of Health, 2021.
- 486 19. Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviews
487 and Meta-Analyses: The PRISMA Statement. *PLOS Medicine* 2009;6(7):e1000097.
488 doi: 10.1371/journal.pmed.1000097
- 489 20. Centers for Disease Control and Prevention. The Vaccine Adverse Event Reporting
490 System (VAERS) results. September 3, 2021. VAERS, 2021.
- 491 21. European Medicines Agency (EMA). Eudravigilance - European database of suspected
492 adverse drug reaction reports, 2021.
- 493 22. Riley DS, Barber MS, Kienle GS, et al. CARE guidelines for case reports: explanation and
494 elaboration document. *J Clin Epidemiol* 2017;89:218-35. doi:
495 <https://doi.org/10.1016/j.jclinepi.2017.04.026>
- 496 23. Chouchana L, Blet A, Al-Khalaf M, et al. Cardiac Inflammation after COVID-19 mRNA
497 Vaccines: A Global Pharmacovigilance Analysis. *medRxiv* 2021:2021.08.12.21261955.
498 doi: 10.1101/2021.08.12.21261955
- 499 24. World Health Organisation (WHO). VigiAccess. Comirnaty: WHO, 2021.
- 500 25. Baggs J, Gee J, Lewis E, et al. The Vaccine Safety Datalink: A Model for Monitoring
501 Immunization Safety. *Pediatrics* 2011;127(Supplement_1):S45-S53. doi:
502 10.1542/peds.2010-1722H
- 503 26. Murthy BP, Zell E, Saelee R, et al. COVID-19 Vaccination Coverage Among Adolescents
504 Aged 12-17 Years - United States, December 14, 2020-July 31, 2021. *Mmwr-*
505 *Morbidity and Mortality Weekly Report* 2021;70(35):1206-13.
- 506 27. Abu Mouch S, Roguin A, Hellou E, et al. Myocarditis following COVID-19 mRNA
507 vaccination. *Vaccine* 2021;39(29):3790-93. doi: 10.1016/j.vaccine.2021.05.087
508 [published Online First: 2021/06/08]
- 509 28. Das BB, Kohli U, Ramachandran P, et al. Myopericarditis after messenger RNA
510 Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age. *J Pediatr*
511 2021;238:26-32. doi: <https://doi.org/10.1016/j.jpeds.2021.07.044> [published Online
512 First: 2021/08/03]
- 513 29. Dionne A, Sperotto F, Chamberlain S, et al. Association of Myocarditis With BNT162b2
514 Messenger RNA COVID-19 Vaccine in a Case Series of Children. *JAMA Cardiol* 2021
515 doi: 10.1001/jamacardio.2021.3471 [published Online First: 2021/08/11]
- 516 30. Fleming-Nouri A, Haimovich AD, Yang D, et al. Myopericarditis in young adults
517 presenting to the emergency department after receiving a second COVID-19 mRNA
518 vaccine. *Acad Emerg Med* 2021;28(7):802-05. doi: 10.1111/acem.14307 [published
519 Online First: 2021/07/27]
- 520 31. Isaak A, Feisst A, Luetkens JA. Myocarditis Following COVID-19 Vaccination. *Radiology*
521 2021;301(1):E378-E79. doi: 10.1148/radiol.2021211766 [published Online First:
522 2021/08/04]

- 523 32. Jain SS, Steele JM, Fonseca B, et al. COVID-19 Vaccination-Associated Myocarditis in
524 Adolescents. *Pediatrics* 2021;148(5) doi: 10.1542/peds.2021-053427 [published
525 Online First: 2021/08/15]
- 526 33. Marshall M, Ferguson ID, Lewis P, et al. Symptomatic Acute Myocarditis in 7 Adolescents
527 After Pfizer-BioNTech COVID-19 Vaccination. *Pediatrics* 2021;148(3) doi:
528 10.1542/peds.2021-052478 [published Online First: 2021/06/06]
- 529 34. McLean K, Johnson TJ. Myopericarditis in a previously healthy adolescent male following
530 COVID-19 vaccination: A case report. *Acad Emerg Med* 2021;28(8):918-21. doi:
531 10.1111/acem.14322 [published Online First: 2021/06/17]
- 532 35. Minocha PK, Better D, Singh RK, et al. Recurrence of Acute Myocarditis Temporally
533 Associated with Receipt of the mRNA Coronavirus Disease 2019 (COVID-19) Vaccine
534 in a Male Adolescent. *J Pediatr* 2021;238:321-23. doi: 10.1016/j.jpeds.2021.06.035
535 [published Online First: 2021/06/25]
- 536 36. Park J, Brekke DR, Bratincsak A. Self-limited myocarditis presenting with chest pain and
537 ST segment elevation in adolescents after vaccination with the BNT162b2 mRNA
538 vaccine. *Cardiol Young* 2021:1-4. doi: 10.1017/S1047951121002547 [published
539 Online First: 2021/06/29]
- 540 37. Schauer J, Buddhe S, Colyer J, et al. Myopericarditis After the Pfizer Messenger
541 Ribonucleic Acid Coronavirus Disease Vaccine in Adolescents. *J Pediatr*
542 2021;238:317-20. doi: 10.1016/j.jpeds.2021.06.083 [published Online First:
543 2021/07/07]
- 544 38. Shaw KE, Cavalcante JL, Han BK, et al. Possible Association Between COVID-19 Vaccine
545 and Myocarditis: Clinical and CMR Findings. *JACC Cardiovasc Imaging*
546 2021;14(9):1856-61. doi: 10.1016/j.jcmg.2021.06.002 [published Online First:
547 2021/07/12]
- 548 39. Snapiri O, Rosenberg Danziger C, Shirman N, et al. Transient Cardiac Injury in
549 Adolescents Receiving the BNT162b2 mRNA COVID-19 Vaccine. *Pediatr Infect Dis J*
550 2021;40(10):e360-e63. doi: 10.1097/INF.0000000000003235 [published Online First:
551 2021/06/03]
- 552 40. Starekova J, Bluemke DA, Bradham WS, et al. Myocarditis Associated with mRNA COVID-
553 19 Vaccination. *Radiology* 2021;301(2):E409-E11. doi: 10.1148/radiol.2021211430
554 [published Online First: 2021/07/21]
- 555 41. Tano E, San Martin S, Girgis S, et al. Perimyocarditis in Adolescents After Pfizer-BioNTech
556 COVID-19 Vaccine. *J Pediatric Infect Dis Soc* 2021;10(10):962-66. doi:
557 10.1093/jpids/piab060 [published Online First: 2021/07/29]
- 558 42. Patel T, Kelleman M, West Z, et al. Comparison of MIS-C Related Myocarditis, Classic
559 Viral Myocarditis, and COVID-19 Vaccine related Myocarditis in Children. *medRxiv*
560 2021:2021.10.05.21264581. doi: 10.1101/2021.10.05.21264581
- 561 43. Ambati S, Colon M, Mihic M, et al. Acute Myopericarditis after COVID-19 Vaccine in
562 Teenagers. *Case Rep Cardiol* 2021;2021:8268755. doi: 10.1155/2021/8268755
563 [published Online First: 2021/10/01]
- 564 44. Lane S, Yeomans A, Shakir S. Reports of myocarditis and pericarditis following mRNA
565 COVID-19 vaccines: A review of spontaneously reported data from the UK, Europe,
566 and the US. *medRxiv* 2021:2021.09.09.21263342. doi: 10.1101/2021.09.09.21263342
- 567 45. Klein NP. Rapid Cycle Analysis to Monitor the Safety of COVID-19 Vaccines in Near Real-
568 Time within the Vaccine Safety Datalink: Myocarditis and Anaphylaxis: Centers for
569 Disease Control, 2021.

- 570 46. Klein NP. Myocarditis Analyses in the Vaccine Safety Datalink: Rapid Cycle Analyses and
571 “Head-to-Head” Product Comparisons: Centres for Disease Control, 2021.
- 572 47. Oster M. mRNA COVID-19 Vaccine-Associated Myocarditis: Centres for Disease Control,
573 2021.
- 574 48. United States Department of Health and Human Services (US DHHS), Centers for Disease
575 Control and Prevention (CDC), National Center for Health Statistics (NCHS).
576 Underlying Cause of Death 1999-2019 on CDC WONDER Online Database, released
577 2020. In: United States Department of Health and Human Services (US DHHS)
578 CfDCaPC, National Center for Health Statistics (NCHS), ed.: Centers for Disease
579 Control and Prevention (CDC), 2021.
- 580 49. Motta M, Stecula D. Quantifying the effect of Wakefield et al. (1998) on skepticism
581 about MMR vaccine safety in the U.S. *PloS one* 2021;16(8):e0256395. doi:
582 10.1371/journal.pone.0256395 [published Online First: 20210819]
- 583 50. Story MT, Neumark-Stzainer DR, Sherwood NE, et al. Management of child and
584 adolescent obesity: attitudes, barriers, skills, and training needs among health care
585 professionals. *Pediatrics* 2002;110(1 Pt 2):210-14.
- 586 51. Henrina J, Putra ICS, Lawrensia S, et al. Cardiac Manifestations, Treatment
587 Characteristics, and Outcomes of Paediatric Inflammatory Multisystem Syndrome
588 Temporally Associated with Severe Acute Respiratory Syndrome Coronavirus-2:
589 systematic review of case reports and case series. *Prog Pediatr Cardiol* 2021:101365.
590 doi: 10.1016/j.ppedcard.2021.101365 [published Online First: 2021/02/16]
- 591 52. Rodriguez-Gonzalez M, Castellano-Martinez A, Cascales-Poyatos HM, et al.
592 Cardiovascular impact of COVID-19 with a focus on children: A systematic review.
593 *World J Clin Cases* 2020;8(21):5250-83. doi: 10.12998/wjcc.v8.i21.5250 [published
594 Online First: 2020/12/04]
- 595 53. Smith C, Odd D, Harwood R, et al. Deaths in children and young people in England after
596 SARS-CoV-2 infection during the first pandemic year. *Nat Med* 2021 doi:
597 10.1038/s41591-021-01578-1 [published Online First: 20211111]
- 598 54. Vasudeva R, Bhatt P, Lilje C, et al. Trends in Acute Myocarditis Related Pediatric
599 Hospitalizations in the United States, 2007-2016. *Am J Cardiol* 2021;149:95-102. doi:
600 10.1016/j.amjcard.2021.03.019 [published Online First: 2021/03/25]
- 601 55. Lota A, Fazal S, Wassall R, et al. National Trends in the Epidemiology of Hospital
602 Admissions for Acute Myocarditis: Insights from the Uk National Health Service.
603 *Journal of the American College of Cardiology* 2018;71(11):A875-A75. doi:
604 10.1016/s0735-1097(18)31416-5
- 605 56. Wu MH, Wu ET, Wang CC, et al. Contemporary Postnatal Incidence of Acquiring Acute
606 Myocarditis by Age 15 Years and the Outcomes From a Nationwide Birth Cohort.
607 *Pediatr Crit Care Med* 2017;18(12):1153-58. doi: 10.1097/PCC.0000000000001363
608 [published Online First: 2017/10/27]
- 609 57. Chou FS, Ghimire LV. Identification of prognostic factors for pediatric myocarditis with a
610 random forests algorithm-assisted approach. *Pediatr Res* 2021;90(2):427-30. doi:
611 10.1038/s41390-020-01268-7 [published Online First: 2020/11/20]
- 612 58. Engler RJ, Nelson MR, Collins LC, Jr., et al. A prospective study of the incidence of
613 myocarditis/pericarditis and new onset cardiac symptoms following smallpox and
614 influenza vaccination. *PLoS One* 2015;10(3):e0118283. doi:
615 10.1371/journal.pone.0118283 [published Online First: 2015/03/21]

- 616 59. Kuntz J, Crane B, Weinmann S, et al. Myocarditis and pericarditis are rare following live
617 viral vaccinations in adults. *Vaccine* 2018;36(12):1524-27. doi:
618 10.1016/j.vaccine.2018.02.030 [published Online First: 2018/02/20]
- 619 60. Su JR, McNeil MM, Welsh KJ, et al. Myopericarditis after vaccination, Vaccine Adverse
620 Event Reporting System (VAERS), 1990-2018. *Vaccine* 2021;39(5):839-45. doi:
621 10.1016/j.vaccine.2020.12.046 [published Online First: 2021/01/11]
- 622 61. Johns Hopkins Bloomberg School of Public Health. Clinical presentation & Prognostic risk
623 factors, vaccines: SARS-CoV-2 mRNA Vaccination-Associated Myocarditis in Children
624 Ages 12-17: A Stratified National Database Analysis 2021 [Available from:
625 [https://ncrc.jhsph.edu/research/sars-cov-2-mrna-vaccination-associated-](https://ncrc.jhsph.edu/research/sars-cov-2-mrna-vaccination-associated-myocarditis-in-children-ages-12-17-a-stratified-national-database-analysis/)
626 [myocarditis-in-children-ages-12-17-a-stratified-national-database-analysis/](https://ncrc.jhsph.edu/research/sars-cov-2-mrna-vaccination-associated-myocarditis-in-children-ages-12-17-a-stratified-national-database-analysis/) accessed
627 06/10/2021.
- 628 62. Shimabukuro TT, Nguyen M, Martin D, et al. Safety monitoring in the Vaccine Adverse
629 Event Reporting System (VAERS). *Vaccine* 2015;33(36):4398-405. doi:
630 10.1016/j.vaccine.2015.07.035 [published Online First: 2015/07/22]
- 631 63. Munro C. Covid-19: Boys are more at risk of myocarditis after vaccination than of
632 hospital admission for covid. *BMJ* 2021;374:n2251. doi: 10.1136/bmj.n2251
633 [published Online First: 2021/09/16]
- 634 64. English C. FDA-Approved Shots Dangerous? VAERS Database Continues To Make Vaccine
635 Skeptics Look Foolish: American Council on Science and Health; 2021 [updated 4
636 June 2021;18 November 2021]. Available from:
637 [https://www.acsh.org/news/2021/06/04/fda-approved-shots-dangerous-vaers-](https://www.acsh.org/news/2021/06/04/fda-approved-shots-dangerous-vaers-database-continues-make-vaccine-skeptics-look-foolish-15583)
638 [database-continues-make-vaccine-skeptics-look-foolish-15583](https://www.acsh.org/news/2021/06/04/fda-approved-shots-dangerous-vaers-database-continues-make-vaccine-skeptics-look-foolish-15583).
- 639

640 Figure 1. PRISMA search flowchart



641

642 **Table 1** - Characteristics and outcomes of the studies describing patients with cardiac adverse effects (myocarditis, pericarditis or myopericarditis
 643 related to COVID-19 vaccination.

Study	Type of study	Number of cases	Case source	Male sex (%)	Age, years (range)	Vaccine type	% Patients presenting after second vaccination	Time between last vaccine and symptom onset, median days (range)	% Patients with symptoms resolved	Median hospitalisation, days (range)
³¹	Case report	1	Single centre, Germany	100	16	BNT 162b2 (Pfizer)	100	1	NR	7
McLean and Johnson ³⁴	Case report	1	Single centre, USA	100	16	BNT 162b2 (Pfizer)	100	3	100	6
Minocha, et al. ³⁵	Case report	1	Single centre, USA	100	17	BNT 162b2 (Pfizer)	100	2	100	6
Starekova, et al. ⁴⁰	Case report	1	Single centre, USA	100	17	BNT 162b2 (Pfizer)	100	2	NR	NR
Abu Mouch, et al. ²⁷	Case report	2	Single centre, Israel	100	16.5 (16-17)	BNT 162b2 (Pfizer)	100	2 (1-3)	100	6 (5-7)
Fleming-Nouri, et al. ³⁰	Case report	2	Single centre, USA	100	16.5 (16-17)	BNT 162b2 (Pfizer)	100	4.5 (2-7)	NR	3 (2-4)
Park, et al. ³⁶	Case report	2	Single centre, USA	100	15.5 (15-16)	BNT 162b2 (Pfizer)	50	2.5 (2-3)	100	4
Shaw, et al. ³⁸	Case report	2	Multiple centres, USA	50	17 (16-17)	BNT 162b2 (Pfizer)	50	3 (2-4)	NR	NR
Ambati, et al. ⁴³	Case report	2	Single centre, USA	100	17 (16-17)	BNT 162b2 (Pfizer)	100	2.5 (2-3)	100	3
Marshall, et al. ³³	Case report	5	Multiple centres, USA	100	16 (14-17)	BNT 162b2 (Pfizer)	100	2 (2-3)	NR	3.5 (2-5)

Snapiri, et al. ³⁹	Case report	7	Multiple centres, Israel	100	16 (16-17)	BNT 162b2 (Pfizer)	86	2 (1-3)	NR	5 (3-6)
Tano, et al. ⁴¹	Case report	8	Single centre, USA	100	16 (15-17)	BNT 162b2 (Pfizer)	75	3 (1-14)	NR	2.5 (1-4)
Patel, et al. ⁴²	Case series	9	Single centre, USA	100	15.7 (IQR: 14.5; 16.6)	Not identified	89	3	100	NR
Schauer, et al. ³⁷	Case report	13	Single centre, USA	92	15 (12-17)	BNT 162b2 (Pfizer)	100*	3 (2-4)	100	2 (1-4)
Dionne, et al. ²⁹	Case series	15	Single centre, USA	93	15 (12-18)	BNT 162b2 (Pfizer)	93	3 (1-6)	73	2 (1-5)
Das, et al. ²⁸	Case series	25	Multiple centres, USA	88	15 (12-17)	BNT 162b2 (Pfizer)	88	2 (<1-20)	100	3 (1-7)
Jain, et al. ³²	Case series	31	Multiple centres, USA	87	12-15. Note that an additional 32 cases aged 16-20y were not included here	BNT 162b2 (Pfizer) mRNA-1273 (Moderna)	97	1.9 (1-3)	NR	2.8 (1-5)

644

645 NR – Not Reported

646 *The authors only considered patients presenting myocarditis after the 2nd dose of the vaccine

647 **Table 2** - Summary of the most common symptoms presented by patients diagnosed with car-
648 *diac adverse effects after being vaccinated against SARS-CoV-2*
649

	N	Number of patients (%)
Symptoms at hospital admission	127	
Chest pain	127	126 (99.2)
Fever	127	44 (34.6)
Shortness of breath	127	26 (20.5)
Weakness	127	22 (17.3)
Headache	127	21 (16.5)
Myalgia	127	18 (14.2)
Nausea	127	11 (8.7)
Vomiting	127	5 (3.9)
Chills	127	5 (3.9)
Tachycardia	127	4 (3.1)
Diaphoresis	127	1 (0.8)
Syncope	127	1 (0.8)
Tingling of fingers	127	1 (0.8)
Laboratory analysis		
Elevated Troponin	127	127 (100)
Elevated C-Reactive Protein	95	92 (96.8)
Electrocardiogram (ECG)	126	
Abnormal	126	93 (73.8)
Diffuse ST changes	126	21 (16.7)
ST segment elevation	126	55 (43.7)
T-wave inversion	126	8 (6.3)
Echocardiogram (Echo)	124	
Systolic or diastolic dysfunction	124	7 (5.6)
Pericardial effusion	124	14 (11.3)
Cardiovascular magnetic resonance (CMR)	91	
Systolic or diastolic dysfunction	91	7 (7.7)
Increased wall thickness	91	2 (2.2)
Pericardial effusion	91	19 (20.9)
Myocardial oedema	91	56 (61.5)
Late gadolinium enhancement (LGE)	91	82 (90.1)
Treatment	121	
NSAID	121	92 (76.0)

IVIG	121	24 (19.8)
Steroid	121	18 (14.9)
Colchicine	121	3 (2.5)
Famotidine	121	3 (2.5)
Aspirin (low dose)	121	2 (1.7)
Enalapril	121	2 (1.7)
Spirolactone	121	2 (1.7)
Furosemide	121	2 (1.7)
Vasopressor	121	2 (1.7)
Narcotic	121	1 (0.8)
No treatment required	121	2 (1.7)

651 *Table 3. Updated data on SARS-CoV-2 vaccination cardiac adverse effects (CAE) (myocarditis and pericarditis) from VAERS and EudraVigilance for*
 652 *children and young people aged between 6 and 17 years old (VAERS) and 3 and 17 years old (EudraVigilance).*
 653


Region		Both sexes			Males			Females			Vaccination date (up to)	Reported CAE date (up to)
		Dose 1	Dose 2	Total	Dose 1	Dose 2	Total	Dose 1	Dose 2	Total		
USA											31/10/2021	31/10/2021
	Number of vaccinations	13,634,026	11,475,125	25,109,151	6,683,248	5,585,905	12,269,153	6,950,778	5,889,220	12,839,998		
	Myocarditis (N)	93	313	406	83	277	360	10	36	46		
	Pericarditis (N)	30	90	120	22	81	103	8	9	17		
EU/EEA											06/11/2021	13/11/2021
	Number of vaccinations	13,925,558	12,004,598	25,930,156								
	Myocarditis (N)	NA	NA	723	NA	NA	626	NA	NA	97		
	Pericarditis (N)	NA	NA	238	NA	NA	172	NA	NA	66		

654

655

656 NA – no data available stratified by dose administered.

657 Figure 2 – Number of cases of myocarditis and pericarditis reported per 1,000,000 of SARS-
658 CoV-2 vaccines administered to children and adolescents (≤ 17 years old) reported to Eudra-
659 Vigilance (EU/EEA) and Vaccine Adverse Event Reporting System (VAERS) (USA).
660



661

662

663 *Figure 3. Crude incidence of cases of myocarditis and pericarditis reported to the Vaccine Adverse Event Reporting System (VAERS) per million*
664 *vaccines, by month of vaccination*

665 Panel A: Myocarditis





